• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research

Menopausal hormone therapy with conjugated equine estrogen is associated with a higher risk of hemorrhagic stroke than therapy with estradiol: a retrospective population-based cohort study
Estrogen therapy is prescribed for women without a uterus. For women with intact uteri, progestogens should be added to protect against endometrial hyperplasia. Different estrogen profiles may cause different side effects and beneficial clinical outcomes [1]. Different forms of estrogen also have different serum E2 concentrations; a previous study demonstrated that 1  mg E2 was equivalent to 0.4 mg CEE [1]. Progestin includes medroxyprogesterone acetate (MPA) and norethindrone acetate (NE). In Taiwan, the most common MHT for patients with an intact uterus are CEE (0.625 mg) or E2 (2 mg) combined with 5 mg MPA or 1 mg NE [2,3].
Source: Maturitas - August 1, 2022 Category: Primary Care Authors: Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding Tags: Original article Source Type: research

MHT in menopausal women at risk: comorbidity cerebrovascular disease
Because stroke incidence increases with age, the absolute risk of stroke associated with standard-dose hormone therapy will be less among women close to the time of menopause, the group of women more likely to consider hormone therapy for vasomotor symptoms. These risks, which are rare but not negligible, should be considered by mid-life women and their physicians when discussing hormone therapy initiation and maintenance for treatment of vasomotor symptoms.
Source: Maturitas - May 14, 2019 Category: Primary Care Authors: Tevfik Yoldemir Tags: INV34 Source Type: research

MHT in myocardial infarction and stroke survivors
30 years ago, it was believed that there is a clear cut protective effect of estrogen in women with coronary artery disease. This was based on studies that monitored the outcomes of postmenopausal hormone therapy (MHT) in women with various basal clinical scenarios, such as myocardial infarction, coronary angiography or coronary artery bypass. These studies were observational, and treatment usually comprised of conjugated equine estrogen alone or combined with medroxyprogesterone acetate. However, results of randomized, placebo-controlled trials (secondary prevention, but mainly primary prevention) pointed at neutrality or...
Source: Maturitas - May 14, 2019 Category: Primary Care Authors: Amos Pines Tags: INV25 Source Type: research

Menopausal Hormone Therapy for the prevention of cardiovascular disease: Evidence-based customization
Boardman et al. provided this March an updated version of their 2013 Cochrane review [1], aiming to assess the effects of menopausal hormone therapy (MHT) for the prevention of cardiovascular disease in postmenopausal women. The authors concluded that treatment with MHT in postmenopausal women, for either primary or secondary prevention of cardiovascular disease, has little, if any, benefit and causes an increase in the risk of stroke and venous thromboembolic events.
Source: Maturitas - May 7, 2015 Category: Primary Care Authors: Dimitrios G. Goulis, Irene Lambrinoudaki Tags: Editorial Source Type: research

Hormone therapy and venous thromboembolism among postmenopausal women
Despite a decrease in postmenopausal hormone therapy (HT) use during the last decade, many women are still prescribed this treatment which remains the most effective to counteract climacteric symptoms. However, HT increases the risk of breast cancer, stroke and venous thromboembolism (VTE) which represents the major harmful effect of short-term duration use. Nevertheless, this benefit/risk ratio has been established among women using oral estrogens alone or combined with a specific progestogen and cannot be necessary extrapolated to other HT.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Marianne Canonico Tags: INV32 Source Type: research

Menopausal hormone therapy, depression, headache, vasomotor symptoms and absence from work: results from 3 years follow up in a Dutch gynecology clinic
Introduction: Use of menopausal hormone therapy (MHT) has dropped worldwide during the last decade after the ‘Women's Health Initiative’ (WHI) trial reported increased breast cancer, stroke and embolism risk. Women with bothersome menopausal complaints resorted to complementary and alternative medications with less or unproven efficacy. Even when indicated use of MHT is low and of short duration, possibly affecting individual wellbeing and ability to work.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Mojdeh Shayesteh, Ingrid Pinas Tags: O5 Source Type: research

Associations between postmenopausal hormone therapy and strokes in a National cohort study
The Women Health Initiative randomized clinical studies on effects of two postmenopausal hormone therapies (HT) were stopped prematurely mainly due to stroke risk.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Ellen Løkkegaard, Anne K. Nielsen, Øjvind Lidegaard Tags: O28 Source Type: research

Menopausal hormone therapy use in 17 European countries during the last decade
Introduction: The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - April 21, 2015 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Tags: O44 Source Type: research

The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Women's Health Initiative: A cohort study
Stroke is the third most common cause of death and the most common cause of prolonged disability in women worldwide[1]. Therefore, the American Heart and Stroke Association recently published strict new guidelines for the prevention of stroke in women [2]. These guidelines acknowledge a number of female gender-related risk factors for stroke, such as migraine, pregnancy, pre-eclampsia, atrial fibrillation, obesity, metabolic syndrome, living alone -status and consequent delay in thrombolysis, and longevity.
Source: Maturitas - April 13, 2015 Category: Primary Care Authors: Pauliina Tuomikoski, Heli Lyytinen, Pasi Korhonen, Fabian Hoti, Pia Vattulainen, Mika Gissler, Olavi Ylikorkala, Tomi S. Mikkola Source Type: research

Menopausal hormone therapy and ovarian cancer: putting risk into perspective
The wide use of menopausal hormone therapy (MHT) rapidly declined a decade ago after the results of the Women's Health Initiative (WHI) showed that women treated with conjugated equine estrogens plus medroxyprogesterone acetate had an increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism [1]. Increased ovarian cancer risk was not reported in the randomized WHI intervention trial nor in the extended poststopping phases of the study [2].
Source: Maturitas - February 26, 2015 Category: Primary Care Authors: Faustino R. Pérez-López, Margaret Rees Source Type: research

Vascular function and cardiovascular risk factors in women with severe flushing
Cardiovascular disease is the leading cause of death in women of postmenopausal age worldwide. It is a relatively rare occurrence before the menopause and the increase in incidence coincides with the most common symptom associated with menopausal transition, hot flushing. Interest in cardiovascular disease post-menopause has largely focused on the effect of hormone therapy on risk of coronary events and stroke, with vasomotor symptoms considered merely a nuisance symptom, but recent work suggests that the presence of flushing may be a marker of underlying cardiovascular disease.
Source: Maturitas - January 24, 2015 Category: Primary Care Authors: Jenifer Sassarini, Mary Ann Lumsden Tags: Review Source Type: research

Menopausal hormone therapy use in 17 European countries during the last decade
The first ‘Women's Health Initiative’ (WHI) randomised controlled trial assessed use of continuous combined menopausal hormone therapy (cc-MHT). It was prematurely stopped because of an increased invasive breast cancer (BC), coronary heart disease (CHD), stroke and pulmonary embolism risk. Consequently, scientific societies recommended use of MHT at the lowest effective dose for the shortest duration. As a result, a sharp decline in MHT use occurred worldwide.
Source: Maturitas - August 4, 2014 Category: Primary Care Authors: Lieveke Ameye, Caroline Antoine, Marianne Paesmans, Evandro de Azambuja, Serge Rozenberg Source Type: research

Hormone therapy and the prevention of cardiovascular disease and cognitive decline: Where do we stand?
Postmenopausal hormone therapy (HT) has long been used for the treatment of menopausal symptoms and urogenital atrophy. Large epidemiological studies have indicated that HT may prevent cardiovascular disease , the Women's Health Initiative (WHI) trial, however, has demonstrated that HT is associated with an increase of cardiovascular outcomes, namely myocardial infarction and stroke . Several reasons have been proposed for this discrepancy, the most important being the old age of the participants, representing thus a population highly divergent from the young, symptomatic recently postmenopausal woman eligible for HT. Estr...
Source: Maturitas - December 6, 2012 Category: Primary Care Authors: Irene Lambrinoudaki, Faustino R. Pérez-López Tags: Editorial Source Type: research